Pyrosequencing for EGFR mutation detection: diagnostic accuracy and clinical implications.

Area of Science:

• Oncology
• Molecular Diagnostics
• Genetics

Background:

• Epidermal Growth Factor Receptor (EGFR) activating mutations are key predictors of treatment response to EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC).
• Accurate mutation screening is essential for guiding therapeutic decisions in NSCLC patients.
• Current standard dideoxy sequencing methods exhibit suboptimal sensitivity for EGFR mutation detection in clinical settings.

Purpose of the Study:

• To evaluate and compare the diagnostic performance of pyrosequencing and dideoxy sequencing for EGFR mutation detection in NSCLC.
• To assess the correlation between pyrosequencing quantitative results and EGFR amplification.
• To determine the clinical utility of pyrosequencing in selecting NSCLC patients for TKI therapy.

Main Methods:

• Retrospective analysis of 53 NSCLC patients treated with TKIs.
• EGFR mutation status determined by both pyrosequencing and dideoxy sequencing.
• Titration assays using cell lines (NCI-H1975, HCC-827) to establish detection limits.
• EGFR copy number assessed by fluorescence in situ hybridization (FISH).

Main Results:

• Pyrosequencing demonstrated a significantly higher detection rate for EGFR mutations compared to dideoxy sequencing.
• Tumor control rates were 86% for mutant EGFR and 29% for wild-type EGFR.
• A positive correlation was observed between high percentages of mutant alleles, EGFR amplification, and clinical response to TKI therapy.

Conclusions:

• Pyrosequencing is a more sensitive method than dideoxy sequencing for EGFR mutation screening in NSCLC.
• Dideoxy sequencing's sensitivity is limited with low mutant allele frequencies or low tumor cellularity.
• Pyrosequencing facilitates quantitative assessment of mutant alleles, correlating with EGFR amplification, and should be utilized for optimal patient selection for TKI therapy.